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Notes on FK 506 
T.E. StarZI. J. Fung, S. Todo, and A. Tzakis 
THANK YOU for inviting me to this wonderful cele· bration. I once wrote my opinion. and meant it 
sincerely, that Roy Calne is one of the greatest surgical 
scientists in the world today, and for that matter in history. 
It could be a heavy burden to have this kind oftalent. But 
Roy is someone who hardly seems to realize that he is 
larger than life. Roy, I salute you for all you have done. but 
even more for what you became personally while doing it. 
It must be a special pleasure for you to have here your 
senior colleague, Joe Murray, to whom you owe so much 
and who in his own tum owes so much to you. as he 
described last night. 
My purpose today is to report briefly on trials with the 
new immunosuppressive drug, FK 506. which now has 
been in clinical use for 19 months. FK 506 has a chemical 
structure which is unrelated to cyclosporine (CyA). It is 
more potent than C y A and has many of the same proper-
ties. including suppression ofT-helper lymphocyte activa-
tion. It suppresses interleukin-2 fIL-2) production and 
expression. and it inhibits the synthesis of other cytokines. 
FK 506 was discovered in 1984 and has been developed 
with astonishing rapidity. All of the pUblications about this 
drug have been since 1987. The rapid progress can be 
traced through the selected citations in the reference 
list. l - lO This report is concerned with clinical trials. 
ALLOGRAFT RESCUE 
FK 506 has been used clinically to rescue more than 200 
liver grafts from being lost to intractable acute or chronic 
rejection under CyA regimens.5 •6 Acute rejection can be 
controlled in three quarters of the cases. and chronic 
rejection in about half. If hepatitis is present. this condition 
may become worse after the switch. 
Ten cardiac recipients have been switched I month to I 
year ago from Cy A to FK 506. 23/4 to 50 months posttrans-
plantation.7 They had gone through multiple bouts of 
biopsy-proven rejection necessitating treatment with anti-
lymphocyte globulin (ALG) preparations, azathioprine 
(AZA) , and augmented steroids. In addition to stopping 
Cy A and AZA. the steroids were lowered or stopped after 
switching to FK 506. One patient whose steroids were 
increased died of aspergillosis and a lymphoma 3 months 
after the drug change. The other nine are well. We believe 
that intractable heart rejection is a very attractive if not 
spectacular indication for switch to FK 506. 
The most difficult rescue is of the kidney graft. We 
believe that this is due partly to the synergistic nephrotox-
icity of Cy A and FK 506 at the time of switch. In addition. 
the rejecting kidney quickly develops combinations of 
severely damaged glomeruli. tubular injury, immune-me-
diated arteritis. or interstitial fibrosis and has little capacity 
for functional recovery. However. of the 21 patients with 
failing renal grafts switched to FK 506. slightly more than 
half have had stabilization and improvement of kidney 
function. 
PRIMARY THERAPY 
The largest experience using FK 506 as primary therapy 
has been with the liver. In 125 consecutive primary trans-
plantations performed up to May 1990. the 6-month and 
subsequent survival of these patients has been >90% with 
graft survival of 88%. S These results have been better than 
in historical controls. The advantages of FK 506 are that it 
is highly effective in controlling rejection and that it can be 
used as monotherapy in most patients after the first several 
weeks. allowing minimal use of steroids. FK 506 can be 
nephrotoxic. but in these cases there was little evidence of 
permanent renal injury and striking freedom from arterial 
hypertension. 
The results with thoracic organ transplantation reflect 
much the same story.7 We have treated two double-lung 
and a heart and lung recipient II to 13 months ago with 
superb results. Further trials with the lung have been 
deferred to be sure that bronchiolitis obliterans will not be 
a threat in the complete absence of steroids. which were 
never used in these three patients. Of 30 pure heart 
recipients, including 8 children treated up to June 1990.26 
(87%) are living. All of the children and a number of the 
adults were taken off steroids within a few weeks. or never 
given prednisone. 
The' value of FK 506 probably is equivalent for kidney 
transplantation. although the high-risk nature of our renal 
case material makes this difficult to prove.9 Through May 
1990, 65 patients were given 66 homografts, all but 2 from 
cadaver donors. Thirty-five percent of the recipients were 
undergoing retransplantation. One of the 65 patients died 
of myocardial infarction for a mortality of 1.5%. Fifty-two 
(80%) are dialysis free 6 to 20 months postoperative. Graft 
survival is 83% in the nonsensitized patients and 73% in 
those sensitized. After 2 months. the prednisone require-
ment of patients with functioning grafts was 0 in 60%, 2.5 
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to 5 mgld in another 15%, and 10 to 20 mgld in the other 
23%. Freedom from hypenension was notewonhy. Serum 
cholesterol levels have oeen low. We are now cngageo In 
a randomized trial of Cy A vs FK 506 regimens. 
It may be that FK 506 will allow success with proce-
dures that have been considered impractical, such as islet 
cell transplantation in humans. One of our islet recipients 
is insulin free more than 10 months after upper abdominal 
exenteration and liver plus islet grafting. and several more 
are close behind. In addition. three small bowel recipients 
(two with simultaneous livers) have been followed for 3 to 
6 months. 
TOXICITY 
As with Cy A. the principal liabilities of FK 506 are 
nephrotoxicity, neurotoxicity. and diabetogenicity. Hair 
and growth disturbances have not been seen. hypenension 
has not been a serious problem. and serum cholesterol and 
uric acid are not much elevated. if at all with FK 506. The 
most imponant factor promoting FK 506 toxicity IS hepatic 
dysfunction. which profoundly influences FK 506 dos-
ing.1O Patients with seriously dysfunctional liver grafts 
may have astronomical rises in FK 506 in spite of reduc-
tion of the FK 506 doses. Under these circumstances. 
severe impairment of renal function will occur and neuro-
toxicity may escalate to coma or convulsions. The risk is 
particularly high during intravenous therapy. Even with 
good liver function. we believe that our intravenous doses 
as originally used were too high and that the total daily 
quantity of intravenous FK 506 probably should be one 
quarter to one third of the planned oral dose instead of the 
half dose which we used in our initial trials. In addition. we 
now believe that continuous (instead of bolus) FK 506 
infusion should be used whenever the IV route is required. 
AUTOIMMUNE DISEASES 
The impact of FK 506 will almost cenainly spread quickly 
beyond transplantation to autoimmune diseases. 1o We 
have already treated patients with the nephrotic syndrome 
secondary to a variety of glomerulonephritides. with re-
mission of proteinuria in six of seven cases. The rapidity of 
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response in autoimmune disorders has been particularly 
easy to follow in skin diseases. We have treated seven 
patients with psonasls. The etfects of FK 506 therapy were 
evident within 48 hours in all. The same rapidity of 
response has been seen in two patients with the wide-
spread disfiguring open sores of pyoderma gangrenosum. 
Other high-priority autoimmune diseases include juve-
nile diabetes mellitus. autoimmune liver disorders (autoim-
mune hepatitis. primary biliary cirrhosis. and sclerosing 
cholangitis). and some of the enteritides. 
CONCLUSION 
FK 506 is a superior immunosuppressive agent that should 
improve patient survival after the commonly performed 
transplant procedures. make feasible transplantations that 
have been previously impractical. and allow immune in-
tervention for serious autoimmune diseases. 
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